Cisplatin-lncorporated hyaluronic acid nanoparticles based on ion-complex formation

Journal of Pharmaceutical Sciences

Volumn 97, Issue 3, 2008, Pages 1268-1276

  Jeong, Young Il ^a   Kim, Seong Taek ^a   Jin, Shu Guang ^a   Ryu, Hyang Hwa ^a   Jin, Yong Hao ^a   Jung, Tae Young ^a   Kim, In Young ^a   Jung, Shin ^a  

^a Chonnam National University   (South Korea)

Author keywords

Cisplatin; Glioma cell; Hyaluronic acid; Hyaluronidase; Nanoparticles

Indexed keywords

CISPLATIN; HYALURONIC ACID; HYALURONIDASE; NANOPARTICLE;

ARTICLE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; HUMAN; HUMAN CELL; NANOTECHNOLOGY; PARTICLE SIZE; TUMOR CELL LINE; CHEMISTRY; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION;

CISPLATIN; HYALURONIC ACID; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; X-RAY DIFFRACTION;

EID: 42949122600     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21103     Document Type: Article

References (30)

1. Laurent TC, Laurent UBG, Fraser JRE. 1995. Functions of hyaluronan. Ann Rheum Dis 54: 429-432.
2. Entwistle J, Hall CL, Turley EA. 1996. Hyaluronan receptors: Regulators of signaling to the cytoskeleton. J Cell Biochem 61:569-577.
3. Knudson CB, Knudson W. 1993. Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J 7:1233-1241.
4. Larsen NE, Leshchiner E, Balaz EA. 1995. Biocom-patibility of Hylan polymers in various tissue compartments. Mater Res Sco Symp Proc 394:149-153.
5. Rooney P, Kumar S, Ponting J, Wang M. 1995. The role of hyaluronan in tumor neovascularization. Int J Cancer 60:632-636.
6. Culty M, Nguyen HA, Underhill CB. 1992. The hyaluronan receptor (CD44) participitates in the uptake and degradation of hyaluronan. J Cell Biol 116:1055-1062.
7. Hall CL, Yang BH, Yang XW, Zhang SW, Turley M, Samuel S, Lange LA, Wang C, Curpen GD, Savani RC, Greenberg AH, Turley EA. 1995. Over-expression of the hyaluronan receptor RHAMM is transforming and is also required for h-ras transformation. Cell 82:19-28.
8. Knudsen W. 1996. Tumor-associated hyaluronan: Providing an extracellular matrix that facilitates invasion. Am J Pathol 148:1721-1726.
9. Yeo TK, Nagy JA, Yeo KT, Dvorak HF, Toole BP. 1996. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 148:1733-1740.
10. Turley EA, Belch AJ, Poppema S, Pilarski LM. 1993. Expression and function of a receptor for hyaluronan-mediated mortility on normal and malignant lymphocytes-B. Blood 81:446-453.
11. Akiyama Y, Jung S, Salhia B, Lee S, Hubbard S, Taylor M, Mainprize T, Akaishi K, Furth W, Rutka JT. 2001. Hyaluronate receptors mediating glioma cell migration and proliferation. J Neurooncol 53: 115-127.
12. Junker N, Latini S, Petersen LN, Kristjansen PE. 2003. Expresstion and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep 10:609-616.
13. Luo Y, Prestwich GD. 1999. Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor biocon-jugate. Bioconjug Chem 10:755-763.
14. Freed LE, Vunjak-Novakovic G, Biron RJ, Eagles DB, Lesnoy DC, Barlow SK, Langer R. 1994. Biodegradable polymer scaffolds for tissue engineering. Biotechnology 12:689-693.
15. Moriyama K, Ooya T, Yui N. 1999. Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation. J Control Release 59:77-86.
16. Vercruysse KP, Prestwich GD. 1998. Hyaluronate derivatives in drug delivery. Crit Rev Ther Drug Carrier Syst 15:513-555.
17. Csoka AB, Frost GI, Stern R. 2001. The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol 20:499-508.
18. Liu DC, Pearlman EP, Diaconu E. 1996. Expression of hyaluronidase by tumor cells angiogenesis in vivo. Proc Natl Acad Sci USA 93:7832-7837.
19. Rosenberg B. 1978. Platinum complexes for the treatment of cancer. Interdiscip Sci Rev 3:134-147.
20. Kartalou M, Essigmann JM. 2001. Mechanism of resistance to cisplatin. Mutat Res 478:23-43.
21. Ponzani V, Bressolle F, Haug IJ, Galtier M, Blayac JP. 1994. Cisplatin-induced renal toxicity and toxicity-modulating strategies: Review. Cancer Chemother Pharmacol 35:1-9.
22. Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS. 2002. PLGA-mPEG nanoparticles of cisplatin: In vitro nanoparticle degradation, in vivo drug release and in vivo drug residence in blood properties. J Control Release 79:123-135.
23. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA. 1999. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 43:1-7.
24. Ohya Y, Masunaga T, Baba T, Ouchi T. 1996. Synthesis and cytotoxic activity of dextran carrying cis-dichloro (cyclohexanetrans-l-1,2-diamine) platinum (II) complex. J Biomater Sci Polym Ed 7:1085-1096.
25. Nishiyama N, Kataoka K. 2001. Preparation and characterization of size-controlled polymeric micelle containing cis-dichlorodiammineplatinium (II) in the core. J Control Release 74:83-94.
26. Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. 2003. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. Cancer Res 63:8977-8983.
27. Li C, Yang DJ, Nikiforow S, Tansey W, Kuang LR, Wright KC, Wallace S. 1994. Formation and characterization of cisplatin-loaded poly(benzyl L-glutamate) microspheres for chemoembolization. Pharm Res 11:1792-1799.
28. Miura RO, Yamagata S, Miura Y, Harada T, Yamagata T. 1995. Analysis of glycosaminoglycan-degrading enzymes by substrate gel electrophoresis (Zymography). Anal Biochem 225:333-340.
29. Delpech B, Laquerriere A, Maingonnat C, Bertrand P, Freger P. 2002. Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res 22:2423-2427.
30. Kreil G. 1995. Hyaluronidases-A group of neglected enzymes. Protein Sci 4:1666-1669.